Hematological Disease
Conditions
Interventions
experimental group:Bendamustine+Busulfan
control group:Fludarabine+Busulfan
Sponsors
Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Primary hematological diseases include acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, lymphoma, myelodysplastic syndrome, and have allogeneic hematopoietic stem cell transplantation indications; 2.Aged 18-70 years, regardless of gender and race; 3.Take the test voluntarily and sign the informed consent form; 4.ECOG score <= 2 points.
Exclusion criteria
Exclusion criteria: 1.Subjects have active infections, such as hepatitis B, tuberculosis, etc.; 2.The subjects main organ function is impaired: with severe cardiac insufficiency, cardiac ejection fraction (EF) less than 60%, or severe arrhythmia, the investigator evaluates those who cannot tolerate the treatment; with severe pulmonary insufficiency (obstruction or restrictive ventilatory disorders), the investigator evaluates those who cannot tolerate the treatment; with severe liver function impairment, the liver function index (ALT, TBIL) is more than 3 times the upper limit of normal (ULN), the investigator evaluates the intolerable Treated patients; with severe renal insufficiency, renal function index (Cr) greater than the upper limit of normal (ULN) more than 2 times, or 24-hour urinary creatinine clearance rate (Ccr) less than 50ml/min, the investigator evaluates those who cannot tolerate treatment; 3.Pregnant and lactating women and patients of childbearing age who are unwilling to take contraceptive measures; 4.There are clinical symptoms of brain dysfunction or serious mental illness, unable to understand or follow the research plan; 5.Combined with other malignant tumors in need of treatment; 6.Patients who cannot guarantee the completion of the necessary treatment plan and follow-up observation; 7.The investigator judges that the subject cannot comply with the research requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate;clinical benefit rate;overall survival;quality of life;vital signs;laboratory indicators;adverse events;serious adverse event; | — |
Countries
China
Contacts
Public ContactLuo Yun
Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University
Outcome results
None listed